Alison Kanski

Articles Authored by Alison Kanski
Less than 1 percent of patients treated at VA hospitals received an off-label therapy, and about a quarter of these patients responded to treatment.

The draft guidance provides suggestions for randomized and single-arm trials to support accelerated approval and confirmatory studies of cancer drugs.

Black Women With High Cancer Risk Lack Access to Genetics Experts, Specialists, OSU Study Finds
Premium
After interviews showed Black women are more likely to seek cancer risk information from PCPs, Ohio State researchers are delving deeper into disparities research.

Baylor Team Aims to Identify Chemo Toxicity Biomarkers in Latino Pediatric Leukemia Patients
Premium
The CPRIT-funded study will examine clinical and genomic data from more than 2,000 Latino patients with acute lymphoblastic leukemia treated with high-dose chemo.
The company will file an NDA by year-end after a third of refractory acute leukemia patients with KMT2A rearrangements or NPM1 mutations had a complete response in a trial.

The Markey Cancer Center is enrolling 500 lung cancer patients from affiliate sites and tracking if MTB-recommended treatments improve their outcomes.

Tailored Phone Calls Increased Rate of Genetic Testing, Counseling for Hereditary Cancer Risk
Premium
A Rutgers Cancer Institute study showed that phone education is more effective at spurring patients to get genetic cancer risk assessment than mailed brochures.

The liquid biopsy assay uses low-pass whole-genome sequencing to screen for copy number alterations in blood, cerebral spinal fluid, and aqueous humor samples.

Study Finds Non-White Representation Gaps in Project GENIE as AACR Works to Diversify Dataset
Premium
Researchers found that the data in the repository as of 2021 wasn't adequately representative of some racial and ethnic groups, but AACR is actively trying to address this disparity.

The company reported solid sales growth from its immunotherapy franchise and strong uptake of CAR T-cell therapies Abecma and Breyanzi.